Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk

Dow Jones05-15

1318 GMT - Oppenheimer analysts say investors could show interest in Aardvark Therapeutics again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. "We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal," the analysts say. "While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market."(kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 15, 2026 09:18 ET (13:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635087277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635087277","market":"us","top_or_hot":-1,"title":"Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1318 GMT - Oppenheimer analysts say investors could show interest in <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. \"We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal,\" the analysts say. \"While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market.\"(kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 09:18 ET (13:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 21:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1318 GMT - Oppenheimer analysts say investors could show interest in <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. \"We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal,\" the analysts say. \"While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market.\"(kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 09:18 ET (13:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635087277","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635087277","pubTimestamp":1778851080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1318 GMT - Oppenheimer analysts say investors could show interest in Aardvark Therapeutics again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. \"We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal,\" the analysts say. \"While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics","BK4007":"制药"},"translate_title":"Aardvark Therapeutics可能会通过即将公布的业绩重新获得投资者的兴趣——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":1.5},"content_text":"1318 GMT - Oppenheimer analysts say investors could show interest in Aardvark Therapeutics again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. \"We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal,\" the analysts say. \"While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market.\"(kelly.cloonan@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 09:18 ET (13:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635087277","isCrawlerRequest":true}